Drug Trial Radar · NCT06983028
Atacicept in Multiple Glomerular Diseases
Last checked: Nov 20, 2026Latest source record: Jun 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
250
Planned (sponsor's estimate)
Start
Jul 7, 2025
Primary completion
Nov 2027
Study completion Nov 2027
Sponsor
- Lead sponsor
- Vera Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- May 21, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 2 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A study to find how well atacicept works and how safe it is in participants with autoimmune kidney disease.
Conditions
- pMN
- IgAN
- Nephrotic Syndrome
- MCD
- FSGS
Interventions
AtaciceptDrug
Atacicept 150 mg SC QW via pre-filled syringe
Primary outcomes
What the sponsor says the trial is designed to measure.
- AE profile and results of routine clinical and laboratory testsTime frame: Baseline until end of study: 52 + 26 Weeks
- Percent reduction in urine protein to creatinine ratio (UPCR)Time frame: Baseline, Week 36
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Vera Therapeutics
Brisbane, California · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.